Role of phytochemicals in the chemoprevention of tumors

Phytochemicals are plant-derived secondary metabolites, which may exert many biological activities in humans, including anticancer properties. Although recent findings appear to support their role in cancer prevention and treatment, this issue is still controversial. Anti-cancer activity of phytochemicals mainly depends on their multi-target mechanism of action, including antimutagenic, antioxidant and antiproliferative activities. Furthermore, they may modulate the host immune response to cancer, reducing inflammatory microenvironment and enhancing lymphocyte onco-surveillance. Since carcinogenesis is multi-factorial and involves several signaling pathways, multi-targeted agents as phytochemicals may represent promising anticancer compounds. This narrative review aims to analyze the current literature on phytochemicals highlighting their specific targets on carcinogenic molecular pathways and their chemopreventive role. A full comprehension of their activity at molecular and cellular levels will contribute for a better understanding of phytochemical clinical efficacy, thus promoting the identification of new effective plant-derived therapeutics.

💡 Research Summary

This narrative review examines the current evidence on plant‑derived phytochemicals as chemopreventive agents against cancer. The authors begin by outlining the multistep, multifactorial nature of carcinogenesis, emphasizing that single‑target drugs often fail to address the complex network of signaling pathways involved in tumor initiation, promotion, and progression. In this context, phytochemicals—secondary metabolites such as polyphenols, flavonoids, terpenoids, and alkaloids—are presented as attractive multi‑target compounds that have been used traditionally for cancer prevention and are now being investigated with modern molecular tools.

A systematic literature search of the past decade (PubMed, Scopus, Web of Science) identified experimental, animal, and early‑phase clinical studies that elucidated the molecular mechanisms of major phytochemicals, including curcumin, epigallocatechin‑3‑gallate (EGCG), resveratrol, genistein, and sulforaphane. The review categorizes their actions into four principal domains: (1) antimutagenic and antioxidant activity, (2) antiproliferative and pro‑apoptotic effects, (3) modulation of oncogenic signaling pathways, and (4) immunomodulation of the tumor microenvironment.

1. Antimutagenic/Antioxidant Effects – Phytochemicals scavenge reactive oxygen species (ROS) and up‑regulate the Nrf2‑ARE antioxidant response, thereby reducing DNA damage and mutagenesis in the early stages of carcinogenesis. Studies show that sulforaphane and EGCG increase glutathione levels and inhibit lipid peroxidation, providing a biochemical shield against genotoxic insults.

2. Antiproliferative/Pro‑Apoptotic Mechanisms – These agents induce cell‑cycle arrest primarily at the G1/S checkpoint by up‑regulating p21, p27, and p53 while down‑regulating cyclin‑D1 and CDK4/6. They also trigger intrinsic apoptosis through mitochondrial outer‑membrane permeabilization, caspase‑3/7 activation, and a shift in the Bcl‑2/Bax ratio. Curcumin and resveratrol have been shown to activate both intrinsic and extrinsic death pathways, enhancing tumor cell susceptibility to programmed cell death.

3. Signal‑Pathway Modulation – Phytochemicals simultaneously target several oncogenic cascades. Curcumin inhibits IκB kinase, suppressing NF‑κB nuclear translocation and downstream inflammatory cytokines (IL‑6, TNF‑α). EGCG blocks PI3K/Akt signaling, reducing survival and proliferation signals. Resveratrol activates SIRT1, leading to p53 de‑acetylation and improved DNA repair. Genistein and sulforaphane interfere with MAPK pathways (ERK, JNK, p38) and STAT3 activation, thereby attenuating angiogenesis, metastasis, and epithelial‑mesenchymal transition. The multi‑target nature reduces the likelihood of resistance that commonly arises with single‑target agents.

4. Immunomodulatory Effects – By re‑educating tumor‑associated macrophages from an M2 (pro‑tumor) to an M1 (anti‑tumor) phenotype, phytochemicals lower the immunosuppressive milieu. They increase Th1‑type cytokines (IL‑12, IFN‑γ) and decrease IL‑10, enhancing natural killer (NK) cell cytotoxicity and CD8⁺ T‑cell surveillance. This immune‑boosting capacity complements their direct cytotoxic actions and may improve responses to immunotherapies.

The review also discusses major translational challenges. Most phytochemicals suffer from poor oral bioavailability, rapid metabolism, and limited tissue distribution, which impede achieving therapeutically relevant plasma concentrations. High doses required for efficacy can cause gastrointestinal discomfort or paradoxical pro‑oxidant effects. To overcome these barriers, the authors highlight nanocarrier systems (liposomes, polymeric nanoparticles, solid lipid nanoparticles) and pro‑drug strategies that improve stability, absorption, and targeted delivery.

Clinical evidence remains preliminary. Small Phase I/II trials with curcumin, EGCG, and sulforaphane have demonstrated safety and modest biomarker modulation (e.g., reduced Ki‑67, lowered circulating inflammatory markers), but definitive proof of cancer incidence reduction is lacking. The authors advocate for well‑designed, randomized controlled trials that incorporate pharmacokinetic monitoring, biomarker‑driven patient selection (e.g., specific oncogenic mutations), and combination regimens with standard chemotherapeutics or immune checkpoint inhibitors.

In conclusion, phytochemicals represent a promising class of multi‑target, low‑toxicity agents capable of intervening at several stages of carcinogenesis. Their ability to modulate oxidative stress, cell‑cycle control, key oncogenic pathways, and the immune microenvironment positions them as attractive candidates for chemoprevention and adjunctive cancer therapy. Realizing this potential will require advances in formulation science, rigorous clinical validation, and integration of molecular biomarkers to identify responsive patient populations.